No Data
No Data
These 4 Measures Indicate That Chengdu Easton Biopharmaceuticals (SHSE:688513) Is Using Debt Reasonably Well
US FDA Approves Easton Biopharma's Abbreviated New Drug Application for Anti-Hypertension Injection
Chengdu Easton Biopharmaceuticals (688513.SH): Nifedipine hydrochloride injection approved by the FDA in the USA for pharmaceutical registration.
Chengdu Easton Biopharmaceuticals (688513.SH) announced on September 9th that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as 'Shuode Pharmaceutical'), recently received a notification from the Food and Drug Administration (FDA) of the United States. Shuode Pharmaceutical's Abbreviated New Drug Application (ANDA) for Nicardipine Hydrochloride Injection, submitted to the US FDA, has been formally approved. The main ingredient of Nicardipine Hydrochloride Injection is nicardipine hydrochloride, indicated for short-term treatment of hypertension when oral administration is not feasible.
Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement stock repurchases in August.
On September 3, Gelunhui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that in August 2024, the company did not implement share repurchases. As of the end of August 2024, the company had repurchased a total of 3,316,769 shares through centralized auction trading, accounting for 1.8788% of the company's current total share capital. The highest purchase price was 56.05 yuan/share and the lowest was 28.12 yuan/share, with a total transaction amount of RMB 123,694,177.73 (excluding stamp duty, transaction commission, and other trading expenses).
chengdu easton biopharmaceuticals (688513.SH): The registration certificate of fluvoxamine maleate tablets for pharmaceutical has been obtained
Chengdu Easton Biopharmaceuticals (688513.SH) announced on September 2nd that its wholly-owned subsidiary Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as "Shuode Pharmaceutical") recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for Fluvoxamine Maleate Tablets. The main ingredient of the tablets is fluvoxamine maleate, indicated for: (1) depression; (2) obsessive-compulsive disorder.
Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) 28% Jump Shows Its Popularity With Investors
No Data
No Data